Clene and its subsidiary Clene Nanomedicine have reported data from RESCUE-ALS long-term, open-label extension clinical trial, where CNM-Au8 substantially boosted survival in patients with amyotrophic lateral sclerosis (ALS).

An oral suspension of gold nanocrystals, CNM-Au8 was developed for restoring neuronal health and function by boosting energy production and usage.

Related Company Profiles

View all

The trial enrolled 45 participants who were randomised into a 1:1 ratio to receive 30mg CNM-Au8 or placebo daily for 36 weeks during the trial’s double-blind portion.

Subsequently, in the open-label portion, the subjects received treatment for up to 130 weeks from randomisation.

As of the data cutoff on 5 July this year, five deaths were reported in the group which was randomised to receive CNM-Au8 compared to 14 in the group initially randomised to receive placebo.

See Also:

Due to inadequate mortality events, median survival from randomisation in the CNM-Au8 group was undefined versus 23.1 months in the placebo arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the unadjusted Kaplan-Meier survival assessments, a substantial survival benefit was demonstrated in subjects initially randomised to the CNM-Au8 treatment group compared to those who received a placebo initially, indicating a 70% decline in mortality risk.

Furthermore, CNM-Au8 was found to be well-tolerated without any significant safety findings observed during the long-term, open-label study period.

Clene president and CEO Rob Etherington said: “We are very pleased to see these results and the apparent survival benefit that our investigational drug, CNM-Au8, appears to provide to people living with ALS.

“At this point, we are awaiting top-line data from the HEALEY ALS Platform Trial, which focuses on endpoints measuring patient function, survival and breathing over a six-month period in a much larger cohort.”